Mathini Ilancheran

ARTICLES BY MATHINI ILANCHERAN

• India’s New Drugs, Medical Devices, And Cosmetics Draft Bill 2022

  11/7/2022

  To accommodate changing requirements and encourage the adoption of new technology, India’s Ministry of Health and Family Welfare released a draft bill in July 2022 to replace the existing Drugs and Cosmetics Act 1940. What are the major areas of change and how much of an impact will there be?

• The Supply & Demand For Clinical Trial Staffing In 2022 & Beyond

  5/5/2022

  The clinical trial staffing market is a high-margin market due to increasing numbers of clinical trials globally and high demand for resources. With the ongoing shortage of CRAs and those in other clinical operations roles, it is important for pharma companies to understand the current trends and how technology providers can help you tackle the attrition problem and manage the growing demand.

• Trends In Decentralized Clinical Trial Remote Monitoring For Medication Adherence

  2/23/2022

  With the implementation of real-time remote monitoring technology, pharmas will be able to do more remote studies that require clinical trial patients to visit sites less frequently. This will remove the burden on patients and improve patient recruitment and retention. This article focuses on the patient medication adherence market.

• Use Of Wearable And Sensor Applications In Clinical Trials Is Booming

  10/26/2021

  Experts predict 50% of clinical trials will incorporate wearables and sensors by 2025, compared to the 10 to 15% at present. This article shares market research on the use of wearables and sensors in clinical trials, including smartwatches, ingestible sensor-embedded pills, and more.

• Decentralized Trials: Trends & Technology Propelling Home Healthcare Services

  6/15/2021

  Moving some trial site activities into patients’ homes has been shown to increase recruitment by 60% or more, and it typically maintains patient retention at over 90%. This article delves into research regarding trends and technology enabling decentralized trials.

• The Asia-Pacific Region: A Hot Spot For Clinical Trials

  3/2/2021

  The Asia-Pacific region has become the hot spot for conducting clinical trials. Why? There is an ease of regulatory compliance, a low cost of conducting studies, a growing patient population, and the presence of a few top clinical institutions acting as sites.

• COVID-19’s Impact On The Clinical Trial Ancillary Supplies Industry

  9/24/2020

  With restrictions on logistics, and countries implementing new restrictions to address increasing COVID-19 cases, it’s important to understand how to manage clinical trials’ ancillary supplies — like sourcing from the right suppliers, managing distribution to all trial sites, stock management, and response to new regulations.

• Analyzing The Top Clinical Trial Technology Trends

  11/29/2019

  Technology plays a critical role in drug development and the R&D value chain by revolutionizing clinical trials and decreasing the failure rate. Though the supply of technology has been increasing and regulation of innovative methods is easing, pharmaceutical companies have been slow to use the emerging technologies, due to the ambiguity prevailing around this space and a highly fragmented supply market. This article outlines the key technologies that have a high impact across trial phases.

• Digital Platforms For Patient Engagement In Clinical Trials — Trends & Outlook

  2/14/2019

  Pharmaceutical companies have three targeted users: physicians, pharmacists, and patients. Various digital platforms are used to create a good customer experience for educating these end users. The core focus is on patients driving patient care, education, and adherence.

• An Introduction To Financial Benchmarking In Biopharma Clinical Development

  10/16/2018

  The high cost and failure rate of new drug candidates going through clinical trials are well documented and a recurring subject of research both by industry and academia.¹ Further, the cost of drug development is a debated topic, and there is no consensus on what the “true cost” is because of the different methods used for these calculations.² The lack of adequate comparable cost data and value measures also makes it difficult for pharmaceutical sponsors and trial sites to implement financial benchmarking for planning, costing, and budget management.